Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis (Q38429617)

3 September 2017

title

Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis (English)

1 reference

3 September 2017

0 references

multiple drug resistance

1 reference

extensively drug-resistant tuberculosis

inferred from title

1 reference

Dick van Soolingen

1 reference

3 September 2017

Keertan Dheda

1 reference

3 September 2017

Neel R Gandhi

1 reference

3 September 2017

Paul Nunn

1 reference

3 September 2017

H Simon Schaaf

1 reference

3 September 2017

Matteo Zignol

1 reference

3 September 2017

Paul Jensen

1 reference

3 September 2017

Jaime Bayona

1 reference

3 September 2017

language of work or name

English

0 references

publication date

1 May 2010

1 reference

3 September 2017

1 reference

3 September 2017

volume

375

1 reference

3 September 2017

issue

9728

1 reference

3 September 2017

page(s)

1830-1843

1 reference

Apocalypse or redemption: responding to extensively drug-resistant tuberculosis.

3 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

The emergence of drug-resistant tuberculosis in New York City

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

Nosocomial Spread of Human Immunodeficiency Virus‐Related Multidrug‐Resistant Tuberculosis in Buenos Aires

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

Nosocomial transmission of multidrug-resistant Mycobacterium tuberculosis in Spain

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

Worldwide emergence of extensively drug-resistant tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

Extensively drug-resistant tuberculosis, Italy and Germany

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in iran.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

Tuberculosis control and elimination 2010–50: cure, care, and social development

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

Slow elimination of multidrug-resistant tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

Modeling the emergence of the 'hot zones': tuberculosis and the amplification dynamics of drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

Antituberculosis drug resistance and anonymous HIV surveillance in tuberculosis patients in Botswana, 2002.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

Doomsday postponed? Preventing and reversing epidemics of drug-resistant tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

Underreported threat of multidrug-resistant tuberculosis in Africa

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

HIV coinfection in multidrug- and extensively drug-resistant tuberculosis results in high early mortality

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

HIV infection and multidrug-resistant tuberculosis: the perfect storm

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

Scratching the surface of ignorance on MDR tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

Challenges in estimating the total burden of drug-resistant tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

Linkage disequilibrium between minisatellite loci supports clonal evolution of Mycobacterium tuberculosis in a high tuberculosis incidence area

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

Mycobacterium tuberculosis growth at the cavity surface: a microenvironment with failed immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

Genetic polymorphism in Mycobacterium tuberculosis isolates from patients with chronic multidrug-resistant tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

Reinfection and mixed infection cause changing Mycobacterium tuberculosis drug-resistance patterns

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

Evolution of the extensively drug-resistant F15/LAM4/KZN strain of Mycobacterium tuberculosis in KwaZulu-Natal, South Africa

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

Standardized treatment of active tuberculosis in patients with previous treatment and/or with mono-resistance to isoniazid: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

Risk of acquired drug resistance during short-course directly observed treatment of tuberculosis in an area with high levels of drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

Transmission of MDR and XDR tuberculosis in Shanghai, China

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

Effect of rpoB mutations conferring rifampin resistance on fitness of Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

Impact of drug resistance on fitness of Mycobacterium tuberculosis strains of the W-Beijing genotype.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

Clinical consequences and transmissibility of drug-resistant tuberculosis in southern Mexico

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

Clusters of multidrug-resistant Mycobacterium tuberculosis cases, Europe

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

Fitness cost of drug resistance in Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

Possible underlying mechanisms for successful emergence of the Mycobacterium tuberculosis Beijing genotype strains

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

Public health impact of isoniazid-resistant Mycobacterium tuberculosis strains with a mutation at amino-acid position 315 of katG: a decade of experience in The Netherlands

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

Time to sputum culture conversion in multidrug-resistant tuberculosis: predictors and relationship to treatment outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

Over the Counter Availability of Antituberculosis Drugs in Tbilisi, Georgia in the Setting of a High Prevalence of MDR-TB

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

Multidrug- and extensively drug-resistant tuberculosis, Germany

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

Fluoroquinolone resistance in Mycobacterium tuberculosis: the effect of duration and timing of fluoroquinolone exposure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

Substandard medicines in resource-poor settings: a problem that can no longer be ignored

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

Natural ventilation for the prevention of airborne contagion

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

The bacteriologic yield in children with intrathoracic tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

Diagnosis and treatment of tuberculosis in children

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

Community-based therapy for children with multidrug-resistant tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

Evaluation of young children in contact with adult multidrug-resistant pulmonary tuberculosis: a 30-month follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

Management of pediatric multidrug-resistant tuberculosis and latent tuberculosis infections in New York City from 1995 to 2003.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

Do fluoroquinolones commonly cause arthropathy in children?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

Multidrug-resistant tuberculosis in children: two cases and a review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

Culture confirmed multidrug resistant tuberculosis: diagnostic delay, clinical features, and outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

Long-term linezolid treatment in a young child with extensively drug-resistant tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

Erasing the World's Slow Stain: Strategies to Beat Multidrug-Resistant Tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

Tuberculosis and HIV-Needed: A New Paradigm for the Control and Management of Linked Epidemics

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

Opportunities and challenges for HIV care in overlapping HIV and TB epidemics

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

Reduced Plasma Concentrations of Antituberculosis Drugs in Patients with HIV Infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

The effect of multiple doses of ritonavir on the pharmacokinetics of rifabutin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

Evaluation of the drug interaction between rifabutin and efavirenz in patients with HIV infection and tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

Transmission of Tuberculosis in New York City -- An Analysis by DNA Fingerprinting and Conventional Epidemiologic Methods

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

The epidemiology of tuberculosis in San Francisco. A population-based study using conventional and molecular methods

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

Tuberculosis in London: the importance of homelessness, problem drug use and prison.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

Tuberculosis in New York City--turning the tide

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

Progress towards improved tuberculosis diagnostics for developing countries

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

Critical role of developing national strategic plans as a guide to strengthen laboratory health systems in resource-poor settings

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

Direct susceptibility testing for multi drug resistant tuberculosis: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

Tuberculosis in the developing world: recent advances in diagnosis with special consideration of extensively drug-resistant tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

Multidrug- and extensively drug-resistant tuberculosis in Africa and South America: epidemiology, diagnosis and management in adults and children

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

Impact of enhanced tuberculosis diagnosis in South Africa: a mathematical model of expanded culture and drug susceptibility testing

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

Epidemiology and clinical management of XDR-TB: a systematic review by TBNET.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

Comprehensive treatment of extensively drug-resistant tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

Early outcomes of MDR-TB treatment in a high HIV-prevalence setting in Southern Africa

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

Aggressive surgical treatment of multidrug-resistant tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

Meropenem-Clavulanate Is Effective Against Extensively Drug-Resistant Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

USPHS Tuberculosis Short-Course Chemotherapy Trial 21: effectiveness, toxicity, and acceptability. The report of final results

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

Randomized trials to optimize treatment of multidrug-resistant tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

Biomarkers for tuberculosis disease activity, cure, and relapse

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

Programmes and principles in treatment of multidrug-resistant tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

Multidrug-resistant tuberculosis management in resource-limited settings

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

Increasing transparency in partnerships for health--introducing the Green Light Committee

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

XDR-TB in South Africa: no time for denial or complacency

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

Short-term Incarceration for the Management of Noncompliance With Tuberculosis Treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

Modeling the impact of tuberculosis control strategies in highly endemic overcrowded prisons

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

Community-based treatment of multidrug-resistant tuberculosis in Lima, Peru: 7 years of experience

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

WHO's new Stop TB Strategy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

Clearing the air. The theory and application of ultraviolet air disinfection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

The detection of airborne transmission of tuberculosis from HIV-infected patients, using an in vivo air sampling model.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

Prevention of nosocomial transmission of extensively drug-resistant tuberculosis in rural South African district hospitals: an epidemiological modelling study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

Tuberculosis among health-care workers in low- and middle-income countries: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

Global tuberculosis drug development pipeline: the need and the reality.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

New vaccines for tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

Novel and improved technologies for tuberculosis diagnosis: progress and challenges

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

Advances in immunotherapy for tuberculosis treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

Upper-room ultraviolet light and negative air ionization to prevent tuberculosis transmission

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

Upper room ultraviolet germicidal irradiation (UVGI) air disinfection on an MDR-TB ward in Sub-Saharan Africa - effects of humidity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

How are we creating fluoroquinolone-resistant tuberculosis?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960410-2

7 January 2021

10.1016/S0140-6736(10)60410-2

Identifiers

DOI

1 reference

release_lw2dhci4c5eoxhgpw4vt3yeeta

3 September 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/lw2dhci4c5eoxhgpw4vt3yeeta

24 November 2022

mapped directly with Wikidata item

1 reference